Danielle Antalffy
Stock Analyst at UBS
(3.62)
# 835
Out of 4,944 analysts
178
Total ratings
50.48%
Success rate
5.71%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMCI Treace Medical Concepts | Maintains: Neutral | $8.6 → $6.5 | $6.90 | -5.80% | 7 | Aug 8, 2025 | |
| RXST RxSight | Maintains: Neutral | $16 → $8 | $8.31 | -3.73% | 4 | Aug 8, 2025 | |
| ENOV Enovis | Maintains: Buy | $65 → $57 | $29.59 | +92.63% | 2 | Aug 8, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $91 → $96 | $103.22 | -6.99% | 5 | Aug 8, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $20 → $17 | $11.13 | +52.74% | 15 | Aug 7, 2025 | |
| INSP Inspire Medical Systems | Maintains: Buy | $270 → $230 | $87.36 | +163.28% | 6 | Aug 5, 2025 | |
| BAX Baxter International | Maintains: Neutral | $35 → $24 | $24.11 | -0.46% | 6 | Aug 4, 2025 | |
| GKOS Glaukos | Maintains: Buy | $125 → $134 | $91.79 | +45.99% | 2 | Jul 31, 2025 | |
| DXCM DexCom | Maintains: Buy | $105 → $106 | $79.96 | +32.57% | 9 | Jul 31, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $130 → $135 | $102.50 | +31.71% | 13 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $547 → $585 | $482.35 | +21.28% | 2 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $190 | $174.42 | +8.93% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $58 | $36.70 | +58.04% | 13 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $14.65 | +10.92% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $95 | $92.91 | +2.25% | 10 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $5 | $4.25 | +17.65% | 2 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $129.40 | +14.37% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $366 → $370 | $378.95 | -2.36% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $77.68 | -3.45% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $1.42 | +58.45% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $308.68 | -9.29% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $13.21 | +6,145.27% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $14.76 | -5.15% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $53.79 | +85.91% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $9.32 | +28.76% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $40.38 | -25.71% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $37.93 | +18.64% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $195.96 | +40.33% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $4.92 | +306.92% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $7.77 | +440.89% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.48 | +522.15% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.08 | +1,288.89% | 1 | Sep 1, 2020 |
Treace Medical Concepts
Aug 8, 2025
Maintains: Neutral
Price Target: $8.6 → $6.5
Current: $6.90
Upside: -5.80%
RxSight
Aug 8, 2025
Maintains: Neutral
Price Target: $16 → $8
Current: $8.31
Upside: -3.73%
Enovis
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $29.59
Upside: +92.63%
Zimmer Biomet Holdings
Aug 8, 2025
Maintains: Sell
Price Target: $91 → $96
Current: $103.22
Upside: -6.99%
Tandem Diabetes Care
Aug 7, 2025
Maintains: Neutral
Price Target: $20 → $17
Current: $11.13
Upside: +52.74%
Inspire Medical Systems
Aug 5, 2025
Maintains: Buy
Price Target: $270 → $230
Current: $87.36
Upside: +163.28%
Baxter International
Aug 4, 2025
Maintains: Neutral
Price Target: $35 → $24
Current: $24.11
Upside: -0.46%
Glaukos
Jul 31, 2025
Maintains: Buy
Price Target: $125 → $134
Current: $91.79
Upside: +45.99%
DexCom
Jul 31, 2025
Maintains: Buy
Price Target: $105 → $106
Current: $79.96
Upside: +32.57%
Boston Scientific
Jul 24, 2025
Maintains: Buy
Price Target: $130 → $135
Current: $102.50
Upside: +31.71%
Jul 23, 2025
Maintains: Neutral
Price Target: $547 → $585
Current: $482.35
Upside: +21.28%
Jul 17, 2025
Maintains: Buy
Price Target: $180 → $190
Current: $174.42
Upside: +8.93%
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $36.70
Upside: +58.04%
Apr 29, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $14.65
Upside: +10.92%
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $92.91
Upside: +2.25%
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $4.25
Upside: +17.65%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $129.40
Upside: +14.37%
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $378.95
Upside: -2.36%
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $77.68
Upside: -3.45%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $1.42
Upside: +58.45%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $308.68
Upside: -9.29%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $13.21
Upside: +6,145.27%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $14.76
Upside: -5.15%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $53.79
Upside: +85.91%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $9.32
Upside: +28.76%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $40.38
Upside: -25.71%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $37.93
Upside: +18.64%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $195.96
Upside: +40.33%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $4.92
Upside: +306.92%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $7.77
Upside: +440.89%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.48
Upside: +522.15%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.08
Upside: +1,288.89%